Studies on Endothelial Cell Cytotoxic Activity in Sera of Patients with Progressive Systemic Sclerosis, Raynaud Syndrome, Rheumatoid Arthritis, and Systemic Lupus Erythematosus

Overview

Journal Rheumatol Int

Specialty Rheumatology

Date 1985 Jan 1

PMID 3880181

Citations 8

Authors

F Drenk

H Mensing

A Serbin

H Deicher

Affiliations

Soon will be listed here.

Abstract

Using human umbilical cord endothelial cell cultures and a modified 3HTdR uptake technique, endothelial cell cytotoxic activity (ECA) has been demonstrated in sera of 95/130 patients with progressive systemic sclerosis (PSS), 14/20 patients with Raynaud syndrome (RS), 52/153 rheumatoid arthritis (RA), and 47/113 systemic lupus erythematosus (SLE) sera. ECA could be enriched by gel filtration from PSS sera in a molecular weight range of 5 k daltons. ECA was partially associated with serum proteins, mainly in the albumin containing fraction, albeit at a lower level of activity. In PSS, no relationship of ECA to the type of skin involvement was observed. ECA appears to be a low molecular weight mediator of, as yet, unknown origin.

Citing Articles

Vascular disease in scleroderma.

Wigley F Clin Rev Allergy Immunol. 2008; 36(2-3):150-75.

PMID: 19067252 DOI: 10.1007/s12016-008-8106-x.

Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension.

Kharitonov S, Cailes J, Black C, du Bois R, Barnes P Thorax. 1998; 52(12):1051-5.

PMID: 9516898 PMC: 1758461. DOI: 10.1136/thx.52.12.1051.

Endothelial cytotoxic activity (ECA) in sera of patients with livedo racemosa generalisata Ehrmann.

Drenk F, Lubach D, Schwabe C, Deicher H Arch Dermatol Res. 1987; 279(6):415-7.

PMID: 3674967 DOI: 10.1007/BF00412630.

Mouse monoclonal antibodies specific for endothelial cells.

Drenk F, Sander U, Alheid U, Serbin A, Deicher H Mol Cell Biochem. 1987; 76(1):67-73.

PMID: 3627115 DOI: 10.1007/BF00219399.

Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases.

Rosenbaum J, Pottinger B, Woo P, Black C, Loizou S, Byron M Clin Exp Immunol. 1988; 72(3):450-6.

PMID: 3168322 PMC: 1541580.

References

FLEISCHMAJER R, Perlish J, West W . Ultrastructure of cutaneous cellular infiltrates in scleroderma. Arch Dermatol. 1977; 113(12):1661-6. View

Hope W, Martin T, Chesterman C, Morgan F . Human beta-thromboglobulin inhibits PGI2 production and binds to a specific site in bovine aortic endothelial cells. Nature. 1979; 282(5735):210-2. DOI: 10.1038/282210a0. View

BOUCEK R, Noble N . Histamine, norepinephrine, and bradykinin stimulation of fibroblast growth and modification of serotonin response. Proc Soc Exp Biol Med. 1973; 144(3):929-33. DOI: 10.3181/00379727-144-37714. View

Kahaleh M, Osborn I, LeRoy E . Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Intern Med. 1982; 96(5):610-3. DOI: 10.7326/0003-4819-96-5-610. View

Kahaleh M, Osborn I, LeRoy E . Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann Intern Med. 1981; 94(4 pt 1):482-4. DOI: 10.7326/0003-4819-94-4-482. View

FLEISCHMAJER R, Perlish J, Duncan M . Scleroderma. A model for fibrosis. Arch Dermatol. 1983; 119(12):957-62. DOI: 10.1001/archderm.119.12.957. View

Raines E, Ross R . Platelet-derived growth factor. I. High yield purification and evidence for multiple forms. J Biol Chem. 1982; 257(9):5154-60. View

Jayson M . Systemic sclerosis--a microvascular disorder?. J R Soc Med. 1983; 76(8):635-42. PMC: 1439277. DOI: 10.1177/014107688307600804. View

Sinclair R, Antonovych T, Mostofi F . Renal proliferative arteriopathies and associated glomerular changes: a light and electron microscopic study. Hum Pathol. 1976; 7(5):565-88. DOI: 10.1016/s0046-8177(76)80103-7. View

10.

Luderschmidt C, Kaulertz I, Konig G, Leisner B . [Progressive systemic scleroderma. Clinical spectrum and prognostic parameters in 131 patients]. Dtsch Med Wochenschr. 1984; 109(37):1389-97. DOI: 10.1055/s-2008-1069383. View

11.

Shanahan Jr W, Korn J . Cytotoxic activity of sera from scleroderma and other connective tissue diseases. Lack of cellular and disease specificity. Arthritis Rheum. 1982; 25(12):1391-5. DOI: 10.1002/art.1780251201. View

12.

GOSPODAROWICZ D, Bialecki H, Greenburg G . Purification of the fibroblast growth factor activity from bovine brain. J Biol Chem. 1978; 253(10):3736-43. View

13.

Kahaleh M, Sherer G, LeRoy E . Endothelial injury in scleroderma. J Exp Med. 1979; 149(6):1326-35. PMC: 2184886. DOI: 10.1084/jem.149.6.1326. View

14.

Norton W, Nardo J . Vascular disease in progressive systemic sclerosis (scleroderma). Ann Intern Med. 1970; 73(2):317-24. DOI: 10.7326/0003-4819-73-2-317. View

15.

Kahaleh M, LeRoy E . Endothelial injury in scleroderma. A protease mechanism. J Lab Clin Med. 1983; 101(4):553-60. View

16.

Ninnemann J, Stockland A . Participation of prostaglandin E in immunosuppression following thermal injury. J Trauma. 1984; 24(3):201-7. DOI: 10.1097/00005373-198403000-00003. View

17.

BOUCEK R, Speropoulos A, Noble N . Serotonin and ribonucleic acid and collagen metabolism of fibroblasts in vitro. Proc Soc Exp Biol Med. 1972; 140(2):599-603. DOI: 10.3181/00379727-140-36512. View

18.

Cohen S, Johnson A, Hurd E . Cytotoxicity of sera from patients with scleroderma. Effects on human endothelial cells and fibroblasts in culture. Arthritis Rheum. 1983; 26(2):170-8. DOI: 10.1002/art.1780260208. View

19.

Hooks J, Moutsopoulos H, Geis S, Stahl N, Decker J, Notkins A . Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979; 301(1):5-8. DOI: 10.1056/NEJM197907053010102. View

20.

MARICQ H, Spencer-Green G, LeRoy E . Skin capillary abnormalities as indicators of organ involvement in scleroderma (systemic sclerosis), Raynaud's syndrome and dermatomyositis. Am J Med. 1976; 61(6):862-70. DOI: 10.1016/0002-9343(76)90410-1. View